Page last updated: 2024-08-23

androstane-3,17-diol and Obesity, Morbid

androstane-3,17-diol has been researched along with Obesity, Morbid in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Du, J; Ge, M; Mizraji, K; Niu, C; Segall-Gutierrez, P; Stanczyk, FZ; Tilley, I	1

Trials

1 trial(s) available for androstane-3,17-diol and Obesity, Morbid

Article	Year
Effect of subcutaneous depot-medroxyprogesterone acetate (DMPA-SC) on serum androgen markers in normal-weight, obese, and extremely obese women. Contraception, 2012, Volume: 86, Issue:6 Topics: Adult; Androgen Antagonists; Androgens; Androstane-3,17-diol; Androstenedione; Biomarkers; Body Mass Index; Contraceptive Agents, Female; Dehydroepiandrosterone Sulfate; Drug Implants; Female; Humans; Medroxyprogesterone Acetate; Obesity; Obesity, Morbid; Sex Hormone-Binding Globulin; Subcutaneous Tissue; Testosterone; Time Factors; Young Adult	2012

Article

Year

Effect of subcutaneous depot-medroxyprogesterone acetate (DMPA-SC) on serum androgen markers in normal-weight, obese, and extremely obese women.

Contraception, 2012, Volume: 86, Issue:6

Topics: Adult; Androgen Antagonists; Androgens; Androstane-3,17-diol; Androstenedione; Biomarkers; Body Mass Index; Contraceptive Agents, Female; Dehydroepiandrosterone Sulfate; Drug Implants; Female; Humans; Medroxyprogesterone Acetate; Obesity; Obesity, Morbid; Sex Hormone-Binding Globulin; Subcutaneous Tissue; Testosterone; Time Factors; Young Adult

2012